MK 2214
Alternative Names: MK-2214Latest Information Update: 06 Oct 2022
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 20 Sep 2022 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (IV) (NCT05466422)
- 20 Jul 2022 Merck plans a phase I trial for Alzheimer's disease (In adults, In the elderly) (NCT05466422)
- 20 Jul 2022 Preclinical trials in Alzheimer's disease in USA (IV)